SCHEMBL2394852

SCHEMBL2394852

CC(=O)N(C)[C@H]1CC[C@H](Oc2cc(F)ccc2[N+](=O)[O-])C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
BCL2A1 Q16548 1/20 0.38
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
ATM Q13315 1/20 0.37
FAAH O00519 1/20 0.36
ACHE P22303 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
HTT P42858 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2390563 0.93 ALDH1A1 (0.46) ALDH1A1MAPTDPP4DPP8DPP9
SCHEMBL2390559 0.93 ALDH1A1 (0.46) ALDH1A1MAPTDPP4DPP8DPP9
SCHEMBL2392995 0.93 ALDH1A1 (0.46) ALDH1A1MAPTDPP4DPP8DPP9
SCHEMBL2369124 0.87 ALDH1A1 (0.40) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL2391387 0.86 GPR119 (0.39) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL16908833 0.86 GPR119 (0.39) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL2473269 0.84 FAAH (0.41) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL2473272 0.84 FAAH (0.41) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL14348238 0.83 RAB9A (0.38) ALDH1A1MAPTL3MBTL1RAB9ATDP1
SCHEMBL2393067 0.82 ALDH1A1 (0.42) ALDH1A1MAPTL3MBTL1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539345-B1 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2015-07-22 EP disclosed
US-8754079-B2 Cycloalkyl containing thienopyrimidines for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-17 US disclosed
US-8754079-B2 Cycloalkyl containing thienopyrimidines for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-17 US disclosed
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-08 US disclosed
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, UCK2 ALDH1A1 4123/4885MAPT 2378/4885DPP4 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.